Immunotherapy in pancreatic cancer: New hope or mission impossible?

Jiang, Jiahong; Zhou, Huaixiang; Ni, Chao; Hu, Xiaoge; Mou, Yiping; Huang, Dongsheng; Yang, Liu

doi:10.1016/j.canlet.2018.10.045

Cited by 28 publications

(18 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The combined effect of these drugs and IFNs indicated that PD-L1 is activated through the JAK–STAT1 pathway by both type I and II IFNs. It also uncovered that JAK–STAT pathway inhibition increases the effectiveness of anti-PD-1 immunotherapy to suppress the growth of PCa 185 . Both type I and II interferon cytokines engage JAK–STAT signaling pathways.…”

Section: In Vitro Studies Of Immune Checkpoint Blockadementioning

confidence: 98%

Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development

Kiaie

Sanaei

Heshmati

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Immunotherapy has been recently considered as a promising alternative for cancer treatment. Indeed, targeting of immune checkpoint (ICP) strategies have shown significant success in human malignancies. However, despite remarkable success of cancer immunotherapy in pancreatic cancer (PCa), many of the developed immunotherapy methods show poor therapeutic outcomes in PCa with no or few effective treatment options thus far. In this process, immunosuppression in the tumor microenvironment (TME) is found to be the main obstacle to the effectiveness of antitumor immune response induced by an immunotherapy method. In this paper, the latest findings on the ICPs, which mediate immunosuppression in the TME have been reviewed. In addition, different approaches for targeting ICPs in the TME of PCa have been discussed. This review has also synopsized the cutting-edge advances in the latest studies to clinical applications of ICP-targeted therapy in PCa.

show abstract

Section: In Vitro Studies Of Immune Checkpoint Blockadementioning

confidence: 98%

Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development

Kiaie

Sanaei

Heshmati

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

show abstract

“…Pancreatic cancer is the fourth leading cause of cancer death and the most frequent gastrointestinal neoplasia, characterized by its lethality with an average survival of 3-6 months and a 5-year survival rate of less than 5% (4)(5)(6). The increase in life expectancy (pancreatic cancer mainly affects the older population), obesity, and diabetes mellitus are the main risk factors for the development of the disease (4)(5)(6). Surgery is the most recommended procedure in the treatment of pancreatic cancer; however, it must be accompanied by adjuvant therapy, which nonetheless guarantees only a 5-year survival rate for patients.…”

Section: Introductionmentioning

confidence: 99%

Can Nimesulide Nanoparticles Be a Therapeutic Strategy for the Inhibition of the KRAS/PTEN Signaling Pathway in Pancreatic Cancer?

et al. 2021

View full text Add to dashboard Cite

Pancreatic cancer is an aggressive, devastating disease due to its invasiveness, rapid progression, and resistance to surgical, pharmacological, chemotherapy, and radiotherapy treatments. The disease develops from PanINs lesions that progress through different stages. KRAS mutations are frequently observed in these lesions, accompanied by inactivation of PTEN, hyperactivation of the PI3K/AKT pathway, and chronic inflammation with overexpression of COX-2. Nimesulide is a selective COX-2 inhibitor that has shown anticancer effects in neoplastic pancreatic cells. This drug works by increasing the levels of PTEN expression and inhibiting proliferation and apoptosis. However, there is a need to improve nimesulide through its encapsulation by solid lipid nanoparticles to overcome problems related to the hepatotoxicity and bioavailability of the drug.

show abstract

“…Both anti-CTLA-4 and anti-PDL-1 have shown promising results in many gastrointestinal malignancies (Sharma and Allison, 2020), however, some studies have approximated the possible role of immunotherapy in periampullary cancers, with relatively conflicting results and unsteady conclusions (Jiang et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

The Expression of Immune Checkpoint Inhibitors PDL-1 and CTLA-4 in Pancreatic Versus Non-Pancreatic Periampullary Adenocarcinoma: An Immunohistochemical Study

El‐Anwar

Nemr

2021

International Journal of Cancer and Biomedical Research

View full text Add to dashboard Cite

It is with great pleasure that I write this editorial to welcome you to the IJCBR. This journal provides a platform for publication of original and reviews research articles, short communications, letter to editor, thesis abstract, conference report, and case studies. These types of publication are directed at the interface of the fields of cancer and biomedical research.The IJCBR relies on a distinguished expert of the Advisory and Editorial Board Members from the top international league covering in depth the related topics. They timely review all manuscripts and maintain highest standards of quality and scientific methodology and ethical concepts. Meanwhile, we take all possible means to keep the time of the publication process as short as possible.I take this chance to welcome your contributions to the IJCBR and have every expectation that it will soon become one of the most respected journals in both the fields of cancer and biomedical research.

show abstract

Immunotherapy in pancreatic cancer: New hope or mission impossible?

Cited by 28 publications

References 108 publications

Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development

Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development

Can Nimesulide Nanoparticles Be a Therapeutic Strategy for the Inhibition of the KRAS/PTEN Signaling Pathway in Pancreatic Cancer?

The Expression of Immune Checkpoint Inhibitors PDL-1 and CTLA-4 in Pancreatic Versus Non-Pancreatic Periampullary Adenocarcinoma: An Immunohistochemical Study

Contact Info

Product

Resources

About